Bioforum Expands Leadership Team with Appointment of Michael Goedde as President
Life Sciences Industry Veteran to Lead Development and Execution of Growth and Innovation Strategy, Expanding Global Reach of Bioforum's Biometric Services and Solutions
Leveraging his extensive experience running worldwide teams and scaling CROs, Goedde will oversee the expansion of Bioforum's industry-leading suite of biometric services and solutions and the formation of strategic partnerships to support this effort. He will report to Bioforum's CEO and Co-Founder
"Michael's proven expertise in biostatistics and clinical data management, and his wealth of experience in pharmaceutical companies, biotechs, and CROs, along with his unwavering dedication to excellence in clinical research, make him exceptionally qualified for this critical leadership role," said Malka. "As we expand our presence in
The addition to Bioforum's executive team comes as it enriches its suite of services in clinical data management, biostatistics and statistical programming, and medical writing, as well as solutions designed to power the automation of key biometric study processes. These include Bioforum's technology-enabled tools for visual analytics (BioGrid), SDTM conversation (JetConvert), and risk analysis and validation (Validify).
Goedde joins Bioforum from ICON plc, where he served as Vice President of Global Data Operations, led a group of more than 600 data operations professionals, and was responsible for developing and executing the company's biometrics and data science-driven clinical data management strategies. Prior to ICON, Goedde spent four years at Parexel in roles of increasing responsibility, most recently as Vice President of Global Data Operations. He headed up a group of more than 900 data operations professionals and Parexel's global business unit for clinical data management and database programming. Earlier in his career, before transitioning to the CRO sector, Goedde worked in clinical data management roles at MedImmune, Human Genome Sciences, Kos Pharmaceuticals, Sanofi, Aventis Pharma, and Hoechst Marion Roussel, where he contributed to numerous new drug approvals in oncology, immunology, CNS, and other therapeutic areas.
"I'm honored to be joining an industry-shaping company known for its people-first culture and to be taking on this role, working alongside a world-class, multidisciplinary team of experts, at such an exciting and pivotal time in Bioforum's journey," said Goedde. "I look forward to expanding our presence and capabilities to support existing clients and introducing more members of the research community to the level of excellence that Bioforum consistently delivers."
An advocate for the clinical data management profession and frequent speaker on the topic at key industry events, Goedde served on the Society for Clinical Data Management (SCDM) Board of Trustees from 2017-2021 and was the Chair of the SCDM Board in 2020. He holds a bachelor's degree in computer science from Computer Lern Zentrum (CLZ) Hoechst AG in
About Bioforum the Data Masters
Bioforum The Data Masters is a leading global clinical research organization (CRO) that specializes in biometric services and solutions for the pharmaceutical, biotech and medical device industries. With a team of experienced professionals and state-of-the-art technology, Bioforum provides a range of services including data management, biostatistics, statistical programming and medical writing to help companies bring new drugs and therapies to market faster. To learn more about us and our services, visit www.bioforumgroup.com or find us on LinkedIn at https://il.linkedin.com/company/bioforum-ltd
Bioforum Contact
Tali Rahinstein
[email protected]
View original content:https://www.prnewswire.com/news-releases/bioforum-expands-leadership-team-with-appointment-of-michael-goedde-as-president-302092887.html
SOURCE Bioforum
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Collective Mining Expands Guayabales Through ANM-Granted Mining Titles Following Public Hearings
- NeuroTherapia to Present Phase 2a Alzheimer's Disease Clinical Data at the AAIC 2026 Conference in London, UK
- Carolina Rush Reports Final Results of Initial Brewer Porphyry Drill Program, Intersects Near-Mine Epithermal Gold-Copper Mineralization
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share